Le Lézard
Classified in: Health
Subjects: LAW, BFA, PLW

ResMed Wins German Patent Infringement Case Brought by Fisher & Paykel


ResMed's AirSense 10, AirCurve 10 and Lumis products do not infringe German utility model patent

MUNICH, Oct. 12, 2017 /CNW/ -- ResMed (NYSE: RMD), the world's leading tech-driven medical device company and innovator in sleep-disordered breathing and respiratory care, today announced that the Munich District Court decided that ResMed's AirSense 10, AirCurve 10, Lumis and their humidifiers do not infringe a Fisher & Paykel German utility model (a short-term patent), DE 20 2013 012 358 U1.

Although ResMed's products do not infringe, ResMed will continue its challenge of the validity of the German utility model before the German Patent and Trademark Office (GPTO). 

To date, no German court has found that ResMed's products infringe a Fisher & Paykel patent in any of the three cases brought by Fisher & Paykel against ResMed in Germany. By contrast, the same German court concluded in September that Fisher & Paykel's Simplus, Eson and Eson 2 masks infringe ResMed patents, while staying the proceedings pending the outcome of invalidation proceedings. ResMed is now defending its own patents in the European Patent Office.     

"We applaud the German court for its sensible approach," said ResMed global general counsel and chief administrative officer David Pendarvis. "We are pleased that the court found our products do not infringe, and look forward to proving that this Fisher & Paykel patent is invalid." 

This ruling in Germany has no impact on ResMed and Fisher & Paykel's patent infringement litigation in other jurisdictions.

About ResMed
ResMed (NYSE:RMD) changes lives with award-winning medical devices and cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 3 million patients remotely monitored every day. Our 6,000-strong team is committed to creating the world's best tech-driven medical device company ? improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 120 countries.

ResMed.com | Facebook | Twitter | LinkedIn

For media:

For investors:

Alison Graves

Agnes Lee

+1 858-836-6789

+1 858-836-5971

[email protected]

[email protected]  

 

ResMed Inc. logo.

 

SOURCE ResMed Inc.


These press releases may also interest you

at 20:35
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

at 19:05
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIOŽ (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...

at 18:42
The Honourable Ya'ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health, will host an event at the University of Manitoba to highlight the federal budget's investments to boost funding for research in Canada. A media...

at 18:18
Targeting a Solution is an insightful and impactful fireside discussion dedicated to ending Veteran suicide that will have its next iteration on April 20th, 2024, in Kannapolis, NC hosted by The Independence Fund. The panel will feature four-term...

at 18:15
Equality Health Foundation, the philanthropic partner of Equality Health LLC and an organization dedicated to advancing health equity and improving well-being access for underserved communities, proudly announces its expansion into Virginia and...

at 18:01
Aflac Incorporated announced today that it has revised the time of its first quarter webcast teleconference call on Thursday, May 2, 2024 to 7:00 a.m. (ET), which is one hour earlier than the originally scheduled 8:00 a.m. start time, to avoid...



News published on and distributed by: